JP2023545182A - イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体 - Google Patents

イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体 Download PDF

Info

Publication number
JP2023545182A
JP2023545182A JP2023522848A JP2023522848A JP2023545182A JP 2023545182 A JP2023545182 A JP 2023545182A JP 2023522848 A JP2023522848 A JP 2023522848A JP 2023522848 A JP2023522848 A JP 2023522848A JP 2023545182 A JP2023545182 A JP 2023545182A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
canine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023522848A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022079138A5 (https=
JP2023545182A5 (https=
Inventor
モージー，モハマド
チャン，ユアンチョン
サハ，アナスヤ
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2023545182A publication Critical patent/JP2023545182A/ja
Publication of JPWO2022079138A5 publication Critical patent/JPWO2022079138A5/ja
Publication of JP2023545182A5 publication Critical patent/JP2023545182A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023522848A 2020-10-15 2021-10-14 イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体 Pending JP2023545182A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063092296P 2020-10-15 2020-10-15
US202063092294P 2020-10-15 2020-10-15
US63/092,296 2020-10-15
US63/092,294 2020-10-15
US202063127184P 2020-12-18 2020-12-18
US63/127,184 2020-12-18
US202163235257P 2021-08-20 2021-08-20
US202163235258P 2021-08-20 2021-08-20
US63/235,257 2021-08-20
US63/235,258 2021-08-20
PCT/EP2021/078385 WO2022079138A1 (en) 2020-10-15 2021-10-14 Caninized rat antibodies to canine interleukin-31 receptor alpha

Publications (3)

Publication Number Publication Date
JP2023545182A true JP2023545182A (ja) 2023-10-26
JPWO2022079138A5 JPWO2022079138A5 (https=) 2024-10-16
JP2023545182A5 JP2023545182A5 (https=) 2024-10-16

Family

ID=78302732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023522848A Pending JP2023545182A (ja) 2020-10-15 2021-10-14 イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体
JP2023522849A Pending JP2023545183A (ja) 2020-10-15 2021-10-14 イヌインターロイキン－３１受容体アルファに対するイヌ化抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023522849A Pending JP2023545183A (ja) 2020-10-15 2021-10-14 イヌインターロイキン－３１受容体アルファに対するイヌ化抗体

Country Status (8)

Country Link
US (2) US20240002518A1 (https=)
EP (2) EP4229084A1 (https=)
JP (2) JP2023545182A (https=)
CN (1) CN116348488A (https=)
AU (2) AU2021359068A1 (https=)
CA (2) CA3194384A1 (https=)
MX (2) MX2023004439A (https=)
WO (2) WO2022079139A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545183A (ja) * 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112491WA (en) * 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
CN120865402A (zh) * 2023-11-27 2025-10-31 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) * 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
WO2020157636A1 (en) * 2019-01-28 2020-08-06 Nestlé Skin Health S.A. Treatment of skin lesions and pruritus in prurigo nodularis patients
JP2023545183A (ja) * 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US11091556B2 (en) * 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN110563844A (zh) 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) * 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
WO2020157636A1 (en) * 2019-01-28 2020-08-06 Nestlé Skin Health S.A. Treatment of skin lesions and pruritus in prurigo nodularis patients
JP2023545183A (ja) * 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 376, no. 9, JPN6025034893, 2 March 2017 (2017-03-02), pages 826 - 835, ISSN: 0005765616 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 383, no. 2, JPN6025034894, 9 July 2020 (2020-07-09), pages 141 - 150, ISSN: 0005765615 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545183A (ja) * 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体
US12577310B2 (en) 2020-10-15 2026-03-17 Intervet Inc. Caninized antibodies to canine interleukin-31 receptor alpha

Also Published As

Publication number Publication date
AU2021359068A1 (en) 2023-06-15
CN116348488A (zh) 2023-06-27
MX2023004439A (es) 2023-05-08
EP4229083A1 (en) 2023-08-23
CA3194384A1 (en) 2022-04-21
AU2021359068A8 (en) 2023-06-22
US12577310B2 (en) 2026-03-17
MX2023004438A (es) 2023-05-08
AU2021360208A1 (en) 2023-04-27
JP2023545183A (ja) 2023-10-26
AU2021360208A9 (en) 2025-03-27
WO2022079139A1 (en) 2022-04-21
WO2022079138A1 (en) 2022-04-21
US20240002518A1 (en) 2024-01-04
CA3194457A1 (en) 2022-04-21
US20230391879A1 (en) 2023-12-07
AU2021359068A9 (en) 2024-06-06
EP4229084A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
JP7719077B2 (ja) アトピー性皮膚炎を処置するための二重特異性イヌ化抗体および二重特異性結合パートナー
CN113861294B (zh) 针对犬白介素-4受体α的抗体
US12577310B2 (en) Caninized antibodies to canine interleukin-31 receptor alpha
JP7727633B2 (ja) イヌインターロイキン－４受容体αに対する抗体
US20250340654A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha ii
JP2025500806A (ja) ヒトｎｇｆに対するイヌ化抗体
CN116472287A (zh) 犬白介素-31受体α的犬源化抗体
RU2855920C1 (ru) Канинизированные антитела против альфа-рецептора интерлейкина-31 собаки
RU2854627C1 (ru) Биспецифические канинизированные антитела для лечения атопического дерматита
CN118891282A (zh) 犬白介素-31受体αII的犬源化抗体
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260331